Literature DB >> 20619282

Lysine 419 targets human glucocorticoid receptor for proteasomal degradation.

Andrew D Wallace1, Yan Cao, Sindhu Chandramouleeswaran, John A Cidlowski.   

Abstract

Glucocorticoid receptors (GRs) are members of a highly conserved family of ligand dependent transcription factors which following hormone binding undergo homologous down-regulation reducing the levels of receptor protein. This decline in human GR (hGR) is due in part to a decrease in protein receptor stability that may limit cellular responsiveness to ligand. To examine the role of the proteasome protein degradation pathway in steroid-dependent hGR responsiveness, we utilized the proteasomal inhibitors MG-132, beta-lactone, and epoxomicin. HeLa cells and COS cells were treated with proteasome inhibitors in the presence of the GR agonist dexamethasone (Dex), or were pretreated with proteasomal inhibitor and then Dex. Dexamethasone induced glucocorticoid responsive reporter activity significantly over untreated controls, whereas cells treated with proteasomal inhibitors and Dex together showed 2-3-fold increase in activity. Protein sequence analysis of the hGR protein identified several candidate protein degradation motifs including a PEST element. Mutagenesis of this element at lysine 419 was done and mutant K419A hGR failed to undergo ligand dependent down-regulation. Mutant K419A hGR displayed 2-3-fold greater glucocorticoid responsive reporter activity in the presence of Dex than wild type hGR. These differences in transcriptional activity were not due to altered subcellular localization, since when the mutant K419A hGR was fused with the green fluorescent protein (GFP) it was found to move in and out of the nucleus similarly to wild type hGR. Together these results suggest that the proteasome and the identified PEST degradation motif limit steroid-dependent human glucocorticoid receptor signaling. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20619282      PMCID: PMC2926287          DOI: 10.1016/j.steroids.2010.06.015

Source DB:  PubMed          Journal:  Steroids        ISSN: 0039-128X            Impact factor:   2.668


  48 in total

1.  The function of steroid hormone receptors is inhibited by the hsp90-specific compound geldanamycin.

Authors:  B Segnitz; U Gehring
Journal:  J Biol Chem       Date:  1997-07-25       Impact factor: 5.157

2.  Stable and specific binding of heat shock protein 90 by geldanamycin disrupts glucocorticoid receptor function in intact cells.

Authors:  L Whitesell; P Cook
Journal:  Mol Endocrinol       Date:  1996-06

3.  Combination of bortezomib, thalidomide, and dexamethasone in the treatment of relapsed, refractory IgD multiple myeloma.

Authors:  Jan Schmielau; Christian Teschendorf; Matthias König; Wolff Schmiegel; Ullrich Graeven
Journal:  Leuk Lymphoma       Date:  2005-04

4.  Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma.

Authors:  Sundar Jagannath; Brian G M Durie; Jeffrey Wolf; Elber Camacho; David Irwin; Jose Lutzky; Marti McKinley; Eli Gabayan; Amitabha Mazumder; David Schenkein; John Crowley
Journal:  Br J Haematol       Date:  2005-06       Impact factor: 6.998

5.  Alternative effects of the ubiquitin-proteasome pathway on glucocorticoid receptor down-regulation and transactivation are mediated by CHIP, an E3 ligase.

Authors:  Xinjia Wang; Donald B DeFranco
Journal:  Mol Endocrinol       Date:  2005-03-10

Review 6.  Proteasome inhibition in multiple myeloma: therapeutic implication.

Authors:  Dharminder Chauhan; Teru Hideshima; Kenneth C Anderson
Journal:  Annu Rev Pharmacol Toxicol       Date:  2005       Impact factor: 13.820

Review 7.  Linking the ubiquitin-proteasome pathway to chromatin remodeling/modification by nuclear receptors.

Authors:  H K Kinyamu; J Chen; T K Archer
Journal:  J Mol Endocrinol       Date:  2005-04       Impact factor: 5.098

8.  Proteasome-mediated proteolysis of estrogen receptor: a novel component in autologous down-regulation.

Authors:  E T Alarid; N Bakopoulos; N Solodin
Journal:  Mol Endocrinol       Date:  1999-09

9.  Ligand-selective targeting of the glucocorticoid receptor to nuclear subdomains is associated with decreased receptor mobility.

Authors:  Marcel J M Schaaf; Laura J Lewis-Tuffin; John A Cidlowski
Journal:  Mol Endocrinol       Date:  2005-02-10

10.  Intragenic sequences of the human glucocorticoid receptor complementary DNA mediate hormone-inducible receptor messenger RNA down-regulation through multiple mechanisms.

Authors:  K L Burnstein; C M Jewell; M Sar; J A Cidlowski
Journal:  Mol Endocrinol       Date:  1994-12
View more
  21 in total

1.  Nuclear bioavailability of the glucocorticoid receptor in a pediatric asthma cohort with variable corticosteroid responsiveness.

Authors:  Salomon Cornejo; Kelan Tantisira; Benjamin A Raby; Scott T Weiss; Feige Kaplan
Journal:  Pediatr Res       Date:  2015-08-13       Impact factor: 3.756

Review 2.  Glucocorticoid receptors: finding the middle ground.

Authors:  Sofie J Desmet; Karolien De Bosscher
Journal:  J Clin Invest       Date:  2017-03-20       Impact factor: 14.808

3.  Selective Glucocorticoid Receptor Modulators (SGRMs) Delay Castrate-Resistant Prostate Cancer Growth.

Authors:  Jacob Kach; Tiha M Long; Phillip Selman; Eva Y Tonsing-Carter; Maria A Bacalao; Ricardo R Lastra; Larischa de Wet; Shane Comiskey; Marc Gillard; Calvin VanOpstall; Diana C West; Wen-Ching Chan; Donald Vander Griend; Suzanne D Conzen; Russell Z Szmulewitz
Journal:  Mol Cancer Ther       Date:  2017-04-20       Impact factor: 6.261

4.  Dexamethasone enhances 1alpha,25-dihydroxyvitamin D3 effects by increasing vitamin D receptor transcription.

Authors:  Alejandro A Hidalgo; Kristin K Deeb; J Wesley Pike; Candace S Johnson; Donald L Trump
Journal:  J Biol Chem       Date:  2011-08-25       Impact factor: 5.157

5.  β-Arrestin-1 inhibits glucocorticoid receptor turnover and alters glucocorticoid signaling.

Authors:  Maria G Petrillo; Robert H Oakley; John A Cidlowski
Journal:  J Biol Chem       Date:  2019-06-05       Impact factor: 5.157

6.  Proteasome inhibition creates a chromatin landscape favorable to RNA Pol II processivity.

Authors:  H Karimi Kinyamu; Brian D Bennett; Pierre R Bushel; Trevor K Archer
Journal:  J Biol Chem       Date:  2019-12-05       Impact factor: 5.157

7.  Differential targeting of androgen and glucocorticoid receptors induces ER stress and apoptosis in prostate cancer cells: a novel therapeutic modality.

Authors:  Alexander Yemelyanov; Pankaj Bhalla; Ximing Yang; Andrey Ugolkov; Kenichi Iwadate; Apollon Karseladze; Irina Budunova
Journal:  Cell Cycle       Date:  2012-01-15       Impact factor: 4.534

8.  Combination of a selective activator of the glucocorticoid receptor Compound A with a proteasome inhibitor as a novel strategy for chemotherapy of hematologic malignancies.

Authors:  Ekaterina Lesovaya; Alexander Yemelyanov; Kirill Kirsanov; Alexander Popa; Gennady Belitsky; Marianna Yakubovskaya; Leo I Gordon; Steven T Rosen; Irina Budunova
Journal:  Cell Cycle       Date:  2012-12-19       Impact factor: 4.534

Review 9.  Exploring the molecular mechanisms of glucocorticoid receptor action from sensitivity to resistance.

Authors:  Sivapriya Ramamoorthy; John A Cidlowski
Journal:  Endocr Dev       Date:  2013-02-01

Review 10.  Glucocorticoid receptor control of transcription: precision and plasticity via allostery.

Authors:  Emily R Weikum; Matthew T Knuesel; Eric A Ortlund; Keith R Yamamoto
Journal:  Nat Rev Mol Cell Biol       Date:  2017-01-05       Impact factor: 94.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.